| 1. Bell J. (2005) Amlexanox for the treatment of recurrent aphthous ulcers.. Clin Drug Investig, 25 (9): (555-66). [PMID:17532700] |
| 2. Spina D. (2008) PDE4 inhibitors: current status.. Br J Pharmacol, 155 (3): (308-15). [PMID:18660825] |
| 3. Elad S, Epstein JB, von Bültzingslöwen I, Drucker S, Tzach R, Yarom N. (2011) Topical immunomodulators for management of oral mucosal conditions, a systematic review; Part II: miscellaneous agents.. Expert Opin Emerg Drugs, 16 (1): (183-202). [PMID:21244328] |
| 4. Reilly SM, Chiang SH, Decker SJ, Chang L, Uhm M, Larsen MJ, Rubin JR, Mowers J, White NM, Hochberg I et al.. (2013) An inhibitor of the protein kinases TBK1 and IKK-ɛ improves obesity-related metabolic dysfunctions in mice.. Nat Med, 19 (3): (313-21). [PMID:23396211] |
| 5. Makino H, Saijo T, Ashida Y, Kuriki H, Maki Y. (1987) Mechanism of action of an antiallergic agent, amlexanox (AA-673), in inhibiting histamine release from mast cells. Acceleration of cAMP generation and inhibition of phosphodiesterase.. Int Arch Allergy Appl Immunol, 82 (1): (66-71). [PMID:2433225] |
| 6. Mowers J, Uhm M, Reilly SM, Simon J, Leto D, Chiang SH, Chang L, Saltiel AR. (2013) Inflammation produces catecholamine resistance in obesity via activation of PDE3B by the protein kinases IKKε and TBK1.. Elife, 2 (3): (e01119). [PMID:24368730] |
| 7. Hansen IS, Krabbendam L, Bernink JH, Loayza-Puch F, Hoepel W, van Burgsteden JA, Kuijper EC, Buskens CJ, Bemelman WA, Zaat SAJ et al.. (2018) FcαRI co-stimulation converts human intestinal CD103+dendritic cells into pro-inflammatory cells through glycolytic reprogramming.. Nat Commun, 9 (1): (863). [PMID:29491406] |
| 8. Adzika GK et al.. (2021) Amlexanox and Forskolin Prevents Isoproterenol-Induced Cardiomyopathy by Subduing Cardiomyocyte Hypertrophy and Maladaptive Inflammatory Responses.. Front Cell Dev Biol, 9 (719351). [PMID:34631707] |
| 9. McCarthy GM et al.. (2018) Chronic ethanol consumption: role of TLR3/TRIF-dependent signaling.. Addict Biol, 23 (3): (889-903). [PMID:28840972] |
| 10. Adzika GK et al.. (2021) Isoproterenol-Induced Cardiomyopathy Recovery Intervention: Amlexanox and Forskolin Enhances the Resolution of Catecholamine Stress-Induced Maladaptive Myocardial Remodeling.. Front Cardiovasc Med, 8 (719805). [PMID:34901202] |
| 11. Sawaged S et al.. (2022) TBK1 and GABARAP family members suppress Coxsackievirus B infection by limiting viral production and promoting autophagic degradation of viral extracellular vesicles.. PLoS Pathog, 18 (8): (e1010350). [PMID:36044516] |
| 12. Zhao P et al.. (2018) TBK1 at the Crossroads of Inflammation and Energy Homeostasis in Adipose Tissue.. Cell, 172 (4): (731-743.e12). [PMID:29425491] |
| 13. Huh JY et al.. (2020) TANK-Binding Kinase 1 Regulates the Localization of Acyl-CoA Synthetase ACSL1 to Control Hepatic Fatty Acid Oxidation.. Cell Metab, 32 (6): (1012-1027.e7). [PMID:33152322] |
| 14. Eintracht J et al.. (2021) Translational readthrough of ciliopathy genes BBS2 and ALMS1 restores protein, ciliogenesis and function in patient fibroblasts.. EBioMedicine, 70 (103515). [PMID:34365092] |
| 15. Zhao P et al.. (2022) The TBK1/IKKe inhibitor amlexanox improves dyslipidemia and prevents atherosclerosis.. JCI Insight, 7 (17): [PMID:35917178] |
C2306574